Vertex announces retirement of Peter Mueller
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals has announced that Dr Peter Mueller, its executive vice-president of global research and development and chief scientific officer, will retire after more than 10 years with the company. Dr Mueller's retirement will be effective 31 October 2014, following a planned transition period, Vertex said. He joined the Boston, Massachusetts-based company in 2003 as chief scientific officer and senior vice-president, drug discovery and innovation. Vertex expects to appoint a new head of global research to oversee the company's drug discovery efforts following Dr Mueller's retirement later this year.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.